This year’s Dermatology Drug Development Summit Europe is hosted in Berlin, Germany, and focuses on research and development in rare dermatological diseases. The 4th summit covers its biggest topics of Atopic dermatitis and Psoarias, as well as rare, autoimmune, and genetic skin diseases, especially Alopecia areata and Vitiligo. The demand for better treatment options and high-quality clinical trials for these rare diseases is growing. As an indistry-lead forum, it provides the latest on clinical developments and innovative technologies with case studies, presentations, interactive workshops.

As one of the expert speakers, Scarletred’s CEO Harald Schnidar, PhD, will be presenting the application of AI-assisted objective skin imaging and analysis of skin diseases and drug effects in clinical trials. Scarletred®Vision provides standardized high-quality mobile and smart skin imaging data. The CE-certified class 1m medical device software is an AI-powered decision support based on machine learning to contribute to a clinical trial’s quality. The presentation will focus on several skin conditions, such as the chronic skin disease Hidradenitis suppurativa, and beyond. Using Scarletred®Vision, new digitial biomarkers and endpoints can be used to improve clinical trials and therefore, find better high-quality relief for patients.

Find out more about the event on their homepage.